Clinical Trial

Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma

Suspended Phase 1/2
View on ClinicalTrials.gov →
Why the trial stopped
PI Request
Summary
To find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma. The effects of this therapy will also be studied.
Protocol Amendment History 2 changes
critical Recruitment suspended 2026-08-01
critical Recruitment suspended: PI Request 2026-08-01
Trial Details
NCT Number NCT05703854
Lead Sponsor M.D. Anderson Cancer Center
Conditions Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma
Enrollment 50 participants
Start Date 2023-03-29
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-31